Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

Vertex Pharmaceuticals has secured two simultaneous ... causing lung infections and problems with digesting food. CFTR modulators like Alyftek and Trikafta work to improve protein function and ...

Now the tricky thing about CF is different gene mutations cause different problems with the protein, but Vertex has managed to develop medicines that are able to treat about 90% of CF patients.

This can cause all sorts of issues, including respiratory problems. CF requires constant care. Vertex markets the only drugs in the world that target the underlying causes of this disease.